member
coronaviru
famili
respons
current
worldwid
pandem
previous
demonstr
five
nucleotid
analogu
inhibit
rnadepend
rna
polymeras
rdrp
includ
activ
triphosph
form
sofosbuvir
alovudin
zidovudin
tenofovir
alafenamid
emtricitabin
report
evalu
librari
addit
nucleosid
triphosph
analogu
varieti
structur
chemic
featur
inhibitor
rdrp
sarscov
featur
includ
modif
sugar
modif
carbocycl
acycl
dideoxynucleotid
base
goal
identifi
nucleotid
analogu
termin
rna
synthesi
catalyz
coronaviru
rdrp
also
potenti
resist
virus
exonucleas
activ
examin
nucleotid
analogu
regard
abil
incorpor
rdrp
polymeras
reaction
prevent
incorpor
molecul
test
display
incorpor
exhibit
immedi
termin
polymeras
reaction
carbovir
triphosph
ganciclovir
triphosph
stavudin
triphosph
entecavir
triphosph
utp
show
delay
termin
cidofovir
diphosph
utp
termin
polymeras
reaction
coronaviru
genom
encod
exonucleas
appar
requir
group
excis
mismatch
base
studi
nucleosid
triphosph
analogu
evalu
form
watsoncricklik
base
pair
nucleotid
analogu
demonstr
termin
either
lack
block
show
delay
termin
nucleotid
may
thu
potenti
resist
exonucleas
activ
properti
investig
futur
furthermor
prodrug
five
nucleotid
analogu
brincidofovircidofovir
abacavir
valganciclovirganciclovir
stavudin
entecavir
fda
approv
viral
infect
safeti
profil
well
known
thu
evalu
rapidli
potenti
therapi
pandem
caus
continu
devast
global
impact
member
orthocoronavirina
subfamili
zhu
et
al
coronavirus
hcv
flavivirus
positivesens
singlestrand
rna
virus
replic
genom
use
rnadepend
rna
polymeras
rdrp
catalyz
reaction
zumla
et
al
dustin
et
al
current
fda
approv
antivir
drug
treatment
human
coronaviru
infect
includ
rdrp
coronavirus
well
establish
drug
target
activ
site
rdrp
highli
conserv
among
positivesens
rna
virus
te
velthui
rdrp
low
fidel
selisko
et
al
allow
recogn
varieti
modifi
nucleotid
analogu
substrat
nucleotid
analogu
may
inhibit
rnapolymeras
catalyz
rna
replic
make
import
candid
antivir
agent
mckenna
et
al
eltahla
et
al
de
clercq
li
rdrp
sarscov
nearli
ident
sequenc
elfiki
recent
rdrp
clone
chien
et
al
rna
polymeras
complex
structur
determin
gao
et
al
help
guid
design
studi
rdrp
inhibitor
remdesivir
phosphoramid
prodrug
contain
modif
sugar
convert
cell
adenosin
triphosph
analogu
shown
inhibitor
rdrp
sarscov
gordon
et
al
current
clinic
trial
sever
countri
therapeut
infect
remdesivir
triphosph
shown
incorpor
higher
effici
atp
coronaviru
rdrp
show
delay
termin
could
help
overcom
excis
viral
exonucleas
gordon
et
al
anoth
prodrug
target
polymeras
shown
broad
spectrum
activ
coronavirus
even
presenc
intact
proofread
function
agostini
et
al
sheahan
et
al
previous
demonstr
five
nucleotid
analogu
inhibit
rnadepend
rna
polymeras
rdrp
includ
activ
triphosph
form
sofosbuvir
alovudin
zidovudin
tenofovir
alafenamid
emtricitabin
ju
et
al
chien
et
al
jockusch
et
al
emtricitabin
tenofovir
alafenamid
use
fda
approv
combin
regimen
treatment
hivaid
hepat
b
viru
hbv
infect
well
preexposur
prophylaxi
prep
prevent
hiv
infect
anderson
et
al
may
evalu
prep
jockusch
et
al
fact
previou
five
nucleotid
analogu
exhibit
inhibit
coronaviru
polymeras
indic
rdrp
accept
varieti
nucleotid
analogu
substrat
work
evalu
addit
nucleotid
analogu
larger
varieti
modif
identifi
effici
termin
well
abil
resist
viru
proofread
function
addit
nucleotid
analogu
select
base
one
follow
criteria
first
structur
chemic
properti
similar
size
structur
natur
nucleotid
includ
abil
fit
within
activ
site
polymeras
b
presenc
modif
posit
absenc
group
result
oblig
termin
polymeras
reaction
c
modif
posit
sugar
base
delay
termin
criteria
provid
structur
chemic
featur
explor
evad
exonucleas
activ
minskaia
et
al
second
previous
shown
inhibit
polymeras
virus
may
also
potenti
inhibit
polymeras
base
previou
work
third
ideal
inhibitor
display
high
select
viral
polymeras
rel
cellular
dna
rna
polymeras
fourth
advantag
consid
nucleotid
analogu
activ
triphosph
form
fdaapprov
drug
drug
known
accept
level
toxic
like
toler
patient
coronaviru
infect
includ
use
select
criteria
examin
nucleotid
analogu
sugar
base
modif
structur
shown
fig
abil
inhibit
sarscov
rdrp
ganciclovir
carbovir
cidofovir
diphosph
stavudin
entecavir
nucleosid
prodrug
form
fda
approv
drug
shown
fig
nucleosid
potenti
prodrug
form
three
other
shown
fig
uridin
analogu
list
investig
inhibitor
viral
polymeras
kumaki
et
al
eyer
et
al
arup
et
al
lauridsen
et
al
triphosph
particular
interest
sinc
demonstr
nucleotid
resist
remov
found
coronavirus
minskaia
et
al
next
briefli
describ
nucleotid
analogu
whose
prodrug
form
fda
approv
viru
infect
ganciclovir
triphosph
gantp
acycl
guanosin
nucleotid
fig
parent
nucleosid
ganciclovir
cytoven
fig
use
treat
aidsrel
cytomegaloviru
cmv
infect
drug
inhibit
herpesvirus
includ
herpesviru
varicella
zoster
viru
cmv
vitro
vivo
valyl
ester
prodrug
valganciclovir
fig
given
oral
cleavag
valyl
ester
ganciclovir
convert
ganciclovir
triphosph
viral
cellular
enzym
matthew
boehm
et
al
carbovir
triphosph
cartp
carbocycl
guanosin
didehydrodideoxynucleotid
fig
parent
prodrug
abacavir
ziagen
fig
fda
approv
nucleosid
revers
transcriptas
inhibitor
hivaid
treatment
faletto
et
al
ray
et
al
taken
oral
well
toler
cidofovir
diphosph
ciddp
acycl
cytidin
nucleotid
fig
prodrug
form
cidofovir
vistid
fig
fda
approv
intraven
treatment
aidsrel
cmv
retin
use
offlabel
varieti
dna
viru
infect
de
clercq
lanier
et
al
parent
prodrug
brincidofovir
bdv
fig
oral
antivir
drug
candid
treat
smallpox
infect
lipid
moieti
mask
phosphat
group
taken
well
cell
low
toxic
activ
wide
rang
dna
virus
anim
includ
poxvirus
adenovirus
herpesvirus
cmv
trost
et
al
cundi
et
al
interestingli
shown
use
vaccinia
viru
dna
polymeras
though
ciddp
incorpor
dna
polymeras
reaction
process
rel
ineffici
termin
synthesi
occur
extens
addit
nucleotid
delay
termin
similar
shown
remdesivir
rdrp
penultim
posit
incorpor
cidofovir
remov
activ
resist
common
cidofovir
mage
et
al
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
stavudin
triphosph
fig
thymidin
analogu
activ
triphosph
form
stavudin
zerit
fig
antivir
use
prevent
treatment
hivaid
ho
hitchcock
preferenti
inhibit
hiv
revers
transcriptas
rt
huang
et
al
lack
group
make
oblig
inhibitor
entecavir
triphosph
enttp
fig
activ
triphosph
form
oral
avail
drug
entecavir
baraclud
fig
guanosin
nucleotid
inhibitor
hbv
rt
matthew
rivkina
rybalow
show
littl
inhibit
nuclear
mitochondri
dna
polymeras
mazzucco
et
al
gener
shown
low
toxic
shown
entecavir
triphosph
delay
chain
termin
revers
transcriptas
make
resist
excis
exonucleas
tchesnokov
et
al
reason
nucleotid
analogu
incorpor
rna
primer
polymeras
reaction
fact
either
lack
normal
sugar
ring
configur
lack
group
would
make
unlik
recogn
involv
proofread
process
decreas
likelihood
develop
resist
inhibit
drug
contrast
mani
rna
virus
sarscov
coronavirus
larg
genom
encod
exonucleas
involv
proofread
shannon
et
al
et
al
activ
enhanc
cofactor
bouvet
et
al
proofread
function
increas
replic
fidel
remov
mismatch
nucleotid
mutat
lead
reduc
replic
fidel
viral
genom
eckerl
et
al
interestingli
complex
effici
excis
singl
mismatch
nucleotid
end
rna
chain
abl
remov
longer
stretch
unpair
nucleotid
modifi
rna
bouvet
et
al
order
nucleotid
analogu
success
inhibitor
virus
need
overcom
proofread
function
coronaviru
exonucleas
activ
typic
requir
presenc
group
end
grow
rna
strand
minskaia
et
al
howev
delay
termin
offend
nucleotid
analogu
longer
end
also
remov
exonucleas
bouvet
et
al
gordon
et
al
nearli
nucleotid
analogu
select
lack
group
modif
block
group
sugar
acycl
nucleotid
deriv
nucleotid
like
substrat
viral
exonucleas
nucleosid
triphosph
nucleosid
triphosph
analogu
purchas
trilink
biotechnolog
dutp
cidofovirdp
ganciclovirtp
dutp
ctp
atp
utp
santa
cruz
biotechnolog
stavudinetp
carbovirtp
moravek
inc
entecavirtp
oligonucleotid
purchas
integr
dna
technolog
inc
idt
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
primer
templat
sequenc
shown
fig
anneal
heat
min
cool
room
temperatur
reaction
buffer
rna
polymeras
mixtur
consist
cofactor
chien
et
al
incub
min
room
temperatur
ratio
reaction
buffer
anneal
templat
primer
solut
contain
templat
primer
reaction
buffer
ad
rna
polymeras
mixtur
incub
addit
min
room
temperatur
final
solut
contain
mm
biotindutp
mm
dbiotinutp
b
mm
c
mm
statp
mm
ciddp
mm
utp
mm
atp
e
mm
cartp
mm
utp
mm
atp
mm
ctp
f
mm
gantp
mm
utp
mm
atp
mm
ctp
g
mm
enttp
mm
utp
mm
atp
mm
ctp
h
mm
mm
dutp
mm
utp
mm
biotindutp
mm
dutp
j
mm
mm
mm
dutp
k
mm
dutp
mm
mm
dutp
l
reaction
buffer
ad
incub
carri
hr
final
concentr
reagent
extens
reaction
nm
rna
primer
nm
rna
templat
biotindutp
dbiotinutp
b
c
statp
ciddp
utp
atp
e
cartp
utp
atp
ctp
f
gantp
utp
atp
ctp
g
enttp
utp
atp
ctp
h
dutp
utp
biotindutp
dutp
j
dutp
k
dutp
dutp
l
reaction
buffer
contain
follow
reagent
mm
trishcl
ph
mm
kcl
mm
mgcl
mm
follow
desalt
use
oligo
clean
concentr
zymo
research
sampl
subject
malditofm
bruker
ultraflextrem
analysi
primer
templat
anneal
heat
min
cool
room
temperatur
reaction
buffer
describ
rna
polymeras
mixtur
consist
cofactor
kirchdoerf
ward
incub
min
room
temperatur
ratio
reaction
buffer
anneal
templat
primer
solut
contain
templat
primer
reaction
buffer
ad
rna
polymeras
mixtur
incub
addit
min
room
temperatur
final
solut
contain
mm
mm
b
mm
c
mm
ciddp
mm
utp
mm
atp
mm
cartp
mm
utp
mm
atp
mm
ctp
e
mm
gantp
mm
utp
mm
atp
mm
ctp
f
reaction
buffer
ad
incub
carri
hr
final
concentr
reagent
extens
reaction
nm
rna
primer
nm
rna
templat
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
test
abil
activ
triphosph
form
nucleotid
analogu
structur
shown
fig
incorpor
rdrp
sarscov
prodrug
molecul
shown
fig
phosphoramid
form
prodrug
readili
synthes
use
protid
approach
alanazi
et
al
rdrp
coronavirus
refer
two
protein
cofactor
shown
requir
process
polymeras
activ
sarscov
subissi
et
al
kirchdoerf
ward
three
compon
coronaviru
polymeras
complex
clone
purifi
describ
previous
kirchdoerf
ward
chien
et
al
perform
polymeras
extens
assay
triphosph
triphosph
triphosph
dutp
biotinutp
dbiotinutp
stavudinetp
statp
cidofovir
diphosph
ciddp
utp
atp
carbovir
triphosph
cartp
utp
atp
ctp
ganciclovir
gantp
utp
atp
ctp
entecavir
triphosph
enttp
utp
atp
ctp
follow
addit
preanneal
rna
templat
primer
preassembl
mixtur
sarscov
andor
rdrp
two
cofactor
protein
also
use
combin
nucleotid
analogu
case
perform
polymeras
reaction
polymeras
reaction
product
analyz
malditofm
sequenc
rna
templat
primer
use
polymeras
extens
assay
correspond
end
genom
indic
top
fig
case
utp
ttp
analogu
two
row
next
avail
posit
templat
rna
polymeras
extens
downstream
prime
site
inde
termin
polymeras
reaction
extens
stop
incorpor
one
nucleotid
analogu
serv
termin
two
base
extens
utp
ttp
analogu
observ
case
ciddp
ctp
analogu
utp
atp
must
provid
allow
extens
point
g
templat
strand
ciddp
incorpor
act
termin
extens
stop
otherwis
addit
incorpor
event
may
observ
similarli
carbovirtp
ganciclovirtp
entecavirtp
gtp
analogu
utp
atp
ctp
must
provid
allow
extens
point
c
templat
strand
cartp
gantp
enttp
incorpor
act
termin
extens
stop
otherwis
addit
incorpor
event
may
observ
guid
polymeras
extens
result
obtain
previous
activ
triphosph
form
sofosbuvir
alovudin
azt
tenofovirdp
emtricitabinetp
ju
et
al
chien
et
al
jockusch
et
al
variou
ratio
nucleotid
chosen
current
work
result
malditof
ms
analysi
primer
extens
reaction
shown
fig
observ
peak
gener
fit
nucleotid
incorpor
pattern
describ
howev
addit
peak
assign
intermedi
stage
extens
reaction
case
extens
beyond
incorpor
nucleotid
analogu
also
observ
describ
result
polymeras
catalyz
reaction
detail
similar
result
obtain
subset
nucleotid
analogu
test
sarscov
rdrp
shown
supplementari
materi
biotindutp
c
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
result
statp
analog
biotindutp
present
fig
case
extens
ms
peak
repres
incorpor
one
da
observ
da
expect
lesser
extent
two
da
observ
da
expect
observ
thu
show
signific
termin
upon
incorpor
indic
potenti
drug
lead
modif
rna
occur
natur
therefor
rel
low
toxic
addit
rna
resist
viral
exonucleas
activ
minskaia
et
al
statp
singl
incorpor
peak
da
observ
da
expect
seen
indic
statp
effici
incorpor
achiev
complet
termin
polymeras
reaction
sinc
molecul
dideoxynucleotid
without
hydroxyl
group
sugar
moieti
may
resist
exonucleas
activ
case
biotindutp
singl
incorpor
peak
evid
da
observ
da
expect
suggest
biotindutp
also
termin
polymeras
reaction
condit
indic
presenc
modif
base
along
absenc
group
nucleotid
analogu
lead
termin
polymeras
reaction
catalyz
rdrp
polymeras
extens
reaction
perform
incub
ciddp
utp
atp
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
result
ctp
analogu
ciddp
oh
group
present
fig
major
peak
observ
indic
incorpor
ciddp
th
posit
initi
prime
site
da
observ
da
expect
base
extens
one
atp
follow
one
ciddp
th
posit
da
observ
da
expect
extens
beyond
posit
indic
delay
termin
ciddp
small
intermedi
peak
also
observ
indic
extens
atp
th
posit
initi
prime
site
follow
first
ciddp
incorpor
da
observ
da
expect
small
partial
utp
extens
peak
da
observ
da
expect
also
observ
essenti
ident
result
obtain
sarscov
polymeras
fig
delay
termin
ciddp
describ
vaccinia
viru
dna
polymeras
mage
et
al
investig
drug
remdesivir
current
test
patient
also
display
delay
termin
gordon
et
al
major
factor
abil
resist
exonucleas
activ
similar
resist
exonucleas
therefor
like
also
occur
cidofovir
due
delay
termin
polymeras
reaction
base
result
cidofovir
oral
prodrug
brincidofovir
thu
potenti
lead
sar
gantp
utp
atp
ctp
c
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
result
gtp
analogu
cartp
enttp
gantp
present
fig
case
extens
first
c
posit
templat
occur
extens
block
presenc
atp
utp
ctp
detail
cartp
major
peak
observ
indic
extens
utp
atp
ctp
follow
complet
termin
cartp
da
observ
da
expect
addit
partial
extens
peak
seen
indic
singl
utp
incorpor
da
observ
da
expect
extens
includ
cartp
da
observ
da
expect
enttp
peak
observ
indic
extens
utp
atp
ctp
follow
complet
termin
singl
enttp
da
observ
da
expect
addit
peak
seen
repres
singl
utp
extens
da
observ
da
expect
major
peak
indic
extens
includ
enttp
da
observ
da
expect
gantp
major
peak
observ
indic
extens
utp
atp
ctp
follow
complet
termin
gantp
da
observ
da
expect
small
peak
repres
extens
includ
gantp
da
observ
da
expect
also
seen
similar
result
obtain
cartp
gantp
use
sarscov
polymeras
fig
cartp
enttp
carbocycl
nucleotid
cartp
lack
group
enttp
lack
group
gantp
acycl
nucleotid
oh
group
lack
ribos
ring
three
thu
may
resist
viral
exonucleas
activ
result
also
indic
cartp
gantp
better
termin
enttp
prodrug
evalu
therapeut
sar
fig
show
sidebysid
comparison
result
use
sarscov
polymeras
result
practic
ident
fig
indic
exhibit
signific
polymeras
reaction
termin
result
consist
oblig
termin
lower
incorpor
effici
repres
small
singleincorpor
peak
da
observ
da
expect
fig
result
shown
incorpor
sarscov
rdrp
incorpor
effici
also
incorpor
opposit
us
templat
strand
appar
mismatch
incorpor
may
due
high
concentr
nucleotid
analogu
use
rel
low
fidel
sarscov
rdrp
result
dbiotinutp
present
fig
dbiotinutp
incorpor
complementari
templat
observ
like
utp
thu
nucleotid
incorpor
termin
polymeras
reaction
result
indic
modif
base
utp
affect
incorpor
activ
rdrp
fig
present
result
experi
dutp
ad
togeth
concentr
major
peak
occur
da
da
expect
repres
incorpor
dutp
adjac
posit
addit
partial
extens
peak
singl
da
observ
da
expect
two
dutp
da
observ
da
expect
found
incorpor
dutp
lack
group
combin
would
enabl
potenti
resist
exonucleas
activ
fig
show
three
mass
spectra
polymeras
reaction
product
use
equimolar
combin
nucleotid
analogu
biotindutp
dutp
utp
b
dutp
c
dutp
dutp
determin
rel
incorpor
effici
base
result
shown
fig
biotindutp
dutp
lower
incorpor
effici
natur
utp
rdrp
sinc
peak
observ
utp
extens
either
one
utp
da
observ
da
expect
two
utp
da
observ
da
expect
fig
seen
incorpor
far
better
dutp
evid
peak
spectrum
da
da
expect
extens
one
da
da
expect
extens
two
final
shown
fig
dutp
effici
incorpor
dutp
reveal
presenc
evid
peak
da
da
expect
extens
one
dutp
da
da
expect
extens
two
dutp
result
indic
dutp
behav
like
utp
termin
polymeras
reaction
neither
dutp
free
group
remain
seen
whether
rna
produc
two
nucleotid
analogu
resist
exonucleas
activ
case
may
consid
use
combin
nucleotid
analogu
effici
termin
sensit
exonucleas
therapeut
purpos
summari
result
demonstr
librari
nucleotid
analogu
test
could
incorpor
rdrp
sarscov
six
nucleotid
analogu
exhibit
complet
termin
polymeras
reaction
cartp
gantp
statp
enttp
biotindutp
two
show
incomplet
delay
termin
ciddp
termin
polymeras
reaction
dutp
dbiotinutp
use
rdrp
sarscov
andor
prodrug
version
shown
fig
avail
readili
synthes
use
protid
approach
alanazi
et
al
prodrug
sever
nucleosid
triphosph
analogu
ganciclovirvalganciclovir
cidofovirbrincidofovir
abacavir
stavudin
entecavir
fda
approv
treatment
viral
infect
toxic
profil
well
establish
thu
result
provid
molecular
basi
evalu
prodrug
viru
inhibit
anim
model
test
efficaci
develop
potenti
therapeut
reduc
drug
resist
would
use
test
combin
protocol
research
support
columbia
univers
grant
jack
foundat
gener
gift
columbia
engin
member
board
visitor
dr
bing
zhao
jj
nation
institut
allergi
infecti
diseas
grant
rnk
patent
applic
work
describ
file
jj
rnk
conceiv
direct
project
approach
assay
design
conduct
jj
xl
sk
sj
jjr
mc
ct
polymeras
associ
protein
nsp
clone
purifi
tka
rnk
data
analyz
author
author
wrote
review
manuscript
exampl
prodrug
activ
triphosph
polymeras
extens
reaction
perform
incub
ciddp
utp
atp
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
cartp
utp
atp
ctp
left
gantp
utp
atp
ctp
right
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
left
right
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
preassembl
sarscov
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
dbiotinutp
atp
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
dutp
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
polymeras
extens
reaction
perform
incub
utp
biotindutp
dutp
dutp
b
dutp
dutp
c
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
shown
method
section
accuraci
mz
determin
da
